MétaCan
Menu
Back to cohort
Record W4413177238 · doi:10.3389/fphar.2025.1599013

Contextual factors in value-based decision support to enhance health technologies adoption: the case of biosimilars

2025· article· en· W4413177238 on OpenAlexaff
Maximilian Otte, Zoltán Kaló, Hussain Abdulrahman Al‐Omar, Meindert Boysen, Yingyao Chen, Ana Paula Beck da Silva Etges, G. Kockaya, Iñaki Gutiérrez‐Ibarluzea, Ahmed Seyam, Hans‐Peter Dauben

Bibliographic record

VenueFrontiers in Pharmacology · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBiosimilars and Bioanalytical Methods
Canadian institutionsInstitute of Health Economics
FundersKing Khalid UniversityMahidol UniversityEwha Womans University
KeywordsBiosimilarOperationalizationStakeholderMultiple-criteria decision analysisKnowledge managementContext (archaeology)Stakeholder engagementBusinessManagement scienceProcess managementMedicineComputer sciencePolitical sciencePublic relationsEconomicsEngineeringOperations research

Abstract

fetched live from OpenAlex

Introduction: Biosimilar medicines play a critical role in enhancing global health outcomes by improving access to effective biologic treatments. However, their acceptance and implementation, particularly in emerging markets, depend not only on clinical evidence but also on the integration of societal, individual, and cultural values. This paper explores how value-based decision-making can support the adoption of biosimilars across diverse contexts. Methods: A multi-stakeholder workshop was conducted with participants from various countries, focusing on decision-making processes for biosimilars in emerging health systems. Discussions addressed stakeholder roles, contextual influences, and the alignment of evidence with values. A Multi-Criteria Decision Analysis (MCDA) framework was proposed as a tool to systematically integrate measurable outcomes and intangible factors such as trust, perceived quality, and cultural acceptance. Results: Key barriers identified included regulatory uncertainties, limited local evidence, regional data protection constraints, and patient preferences for originator biologics. Participants emphasized the importance of adaptable frameworks that reflect local cultural, economic, and systemic conditions. The proposed MCDA approach was viewed as a promising method for capturing complex value dimensions and facilitating transparent, inclusive decision-making. Broader societal benefits of biosimilars, such as economic development through local production, were also highlighted. Discussion: The workshop underscored the need for value-sensitive implementation strategies that go beyond clinical effectiveness. Integrating context-specific values into evidence-based decision-making can foster trust and support the sustainable adoption of biosimilars. The MCDA framework offers a structured approach to operationalize these principles. Future research should test and refine this model in varied health system settings to support its practical application by policymakers, healthcare providers, and industry stakeholders.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.045
metaresearch head score (Gemma)0.049
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.045
Threshold uncertainty score0.240

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0450.049
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.002
Science and technology studies0.0090.013
Scholarly communication0.0150.008
Open science0.0020.012
Research integrity0.0050.004
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.366
Teacher spread0.349 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueFrontiers in PharmacologySame topicBiosimilars and Bioanalytical MethodsFrench-language works237,207